What are the key takeaways from this Biotech Hangout episode?

Key insights include: **Biotech Market Bifurcation:** XBI outperforms the broader market year-to-date, but returns are highly uneven. Funds with mandatory short exposure struggled as heavily-shorted stocks like Kinetics and Apogee were acquired without warning. Investors tracking biotech should monitor short interest in liquid, catalyst-light names, as unexpected takeouts can rapidly compress those positions.; **Clinical Trial Design Risk:** Siona's CF trial enrolled only 14 patients and measured sweat chloride reduction as a pharmacodynamic proxy, targeting a 10 mmol threshold. Results showed only 1 mmol reduction, a 90% stock decline followed. Small proof-of-concept studies using surrogate biomarkers carry outsized binary risk; investors should scrutinize sample size and endpoint predictiveness before building positions.; **Psychedelics Durability Signal:** Definium's phase three generalized anxiety disorder study showed a statistically significant effect size at 12 weeks post single-dose LSD administration, supporting once-quarterly or less frequent dosing. FDA's psych division now requires anxiety trials to exclude patients with comorbid depression to confirm pseudo-specificity, a design standard that future psychedelics programs should incorporate proactively.

What did Greg Suwanaway and Paul Matisse discuss on Biotech Hangout?

Biotech Hangout Episode 193 covers XBI market performance, two high-profile clinical failures (10x Genomics HFpEF trial, Siona CF trial), the Jazz Pharmaceuticals $1.3B Actio acquisition, positive psychedelics phase three data from Definium, and the ongoing US-China biotech protectionism debate. Key topics include: **Biotech Market Bifurcation:** XBI outperforms the broader market year-to-date, but returns are highly uneven. Funds with mandatory short exposure struggled as heavily-shorted stocks like Kinetics and Apogee were acquired without warning. Investors tracking biotech should monitor short interest in liquid, catalyst-light names, as unexpected takeouts can rapidly compress those positions.; **Clinical Trial Design Risk:** Siona's CF trial enrolled only 14 patients and measured sweat chloride reduction as a pharmacodynamic proxy, targeting a 10 mmol threshold. Results showed only 1 mmol reduction, a 90% stock decline followed. Small proof-of-concept studies using surrogate biomarkers carry outsized binary risk; investors should scrutinize sample size and endpoint predictiveness before building positions..

How long is this episode of Biotech Hangout?

This episode is 59 minutes long. SignalCast provides an AI-generated summary so you can get the key insights in about 3 minutes.

Biotech Hangout

Episode 193 - August 14, 2026

August 14, 2026

59 min episode · 2 min read

Greg Suwanaway,Paul Matisse,Tess Cameron

Episode

59 min

Read time

2 min

Topics

Relationships, Investing, Fundraising & VC

AI-Generated Summary

Published Aug 15, 2026

Key Takeaways

✓Biotech Market Bifurcation: XBI outperforms the broader market year-to-date, but returns are highly uneven. Funds with mandatory short exposure struggled as heavily-shorted stocks like Kinetics and Apogee were acquired without warning. Investors tracking biotech should monitor short interest in liquid, catalyst-light names, as unexpected takeouts can rapidly compress those positions.
✓Clinical Trial Design Risk: Siona's CF trial enrolled only 14 patients and measured sweat chloride reduction as a pharmacodynamic proxy, targeting a 10 mmol threshold. Results showed only 1 mmol reduction, a 90% stock decline followed. Small proof-of-concept studies using surrogate biomarkers carry outsized binary risk; investors should scrutinize sample size and endpoint predictiveness before building positions.
✓Psychedelics Durability Signal: Definium's phase three generalized anxiety disorder study showed a statistically significant effect size at 12 weeks post single-dose LSD administration, supporting once-quarterly or less frequent dosing. FDA's psych division now requires anxiety trials to exclude patients with comorbid depression to confirm pseudo-specificity, a design standard that future psychedelics programs should incorporate proactively.
✓China Partnership Strategy: Revolution Medicines structured a deal with BioNTech subsidiary B1 exchanging China commercialization rights for its RAS portfolio in return for clinical collaboration access to B1's PRMT5 and EGFR-MET trispecific assets. Companies with strong pipelines can use regional rights as non-dilutive currency to access complementary mechanisms without building costly local commercial infrastructure.
✓Post-Acquisition Safety Risk: Amgen's Tavneos faced EMA withdrawal after evidence emerged that ChemoCentryx, acquired in 2022, had unblinded trial data, reclassified nine patients as responders, and filed on manipulated p-values. Acquirers should conduct independent statistical audits of pivotal trial patient-level datasets during due diligence, not solely relying on regulatory submission summaries or management representations.

What It Covers

Biotech Hangout Episode 193 covers XBI market performance, two high-profile clinical failures (10x Genomics HFpEF trial, Siona CF trial), the Jazz Pharmaceuticals $1.3B Actio acquisition, positive psychedelics phase three data from Definium, and the ongoing US-China biotech protectionism debate.

Key Questions Answered

•Biotech Market Bifurcation: XBI outperforms the broader market year-to-date, but returns are highly uneven. Funds with mandatory short exposure struggled as heavily-shorted stocks like Kinetics and Apogee were acquired without warning. Investors tracking biotech should monitor short interest in liquid, catalyst-light names, as unexpected takeouts can rapidly compress those positions.
•Clinical Trial Design Risk: Siona's CF trial enrolled only 14 patients and measured sweat chloride reduction as a pharmacodynamic proxy, targeting a 10 mmol threshold. Results showed only 1 mmol reduction, a 90% stock decline followed. Small proof-of-concept studies using surrogate biomarkers carry outsized binary risk; investors should scrutinize sample size and endpoint predictiveness before building positions.
•Psychedelics Durability Signal: Definium's phase three generalized anxiety disorder study showed a statistically significant effect size at 12 weeks post single-dose LSD administration, supporting once-quarterly or less frequent dosing. FDA's psych division now requires anxiety trials to exclude patients with comorbid depression to confirm pseudo-specificity, a design standard that future psychedelics programs should incorporate proactively.
•China Partnership Strategy: Revolution Medicines structured a deal with BioNTech subsidiary B1 exchanging China commercialization rights for its RAS portfolio in return for clinical collaboration access to B1's PRMT5 and EGFR-MET trispecific assets. Companies with strong pipelines can use regional rights as non-dilutive currency to access complementary mechanisms without building costly local commercial infrastructure.
•Post-Acquisition Safety Risk: Amgen's Tavneos faced EMA withdrawal after evidence emerged that ChemoCentryx, acquired in 2022, had unblinded trial data, reclassified nine patients as responders, and filed on manipulated p-values. Acquirers should conduct independent statistical audits of pivotal trial patient-level datasets during due diligence, not solely relying on regulatory submission summaries or management representations.

Notable Moment

Definium's phase three anxiety trial deliberately excluded patients with comorbid depression to prove the drug's effect was anxiety-specific, not a byproduct of improving mood. Despite this population de-enrichment, the effect size remained large at 12 weeks post-dose, a result the panel described as difficult to explain mechanistically.

Know someone who'd find this useful?

Episode Transcript

You're listening to Bio Tech Hangout, a live and unedited weekly discussion of all the latest news in our industry with a group of biotech leaders and experts. I'm Chris Garabedian, and my cohost today are Greg Suwanaway, Paul Matisse, and Tess Cameron. For more information about our hosts and guest speakers or to listen to the most recent episode, please go to biotechhangout.com. So so, Tess, we we often like to just start with, a pulse on the markets. Would you like to share how are you thinking about, the public markets, as we sit here today? You know, public markets have been really positive. You know, the XBI, you know, has has been, you know, performing performing really well. And, you know, I think what's important though is that we are seeing strong performance, but we are also seeing kind of selective performance. Right? So it's not, it's not that, like, everything is going up. Right? It's like IPOs are performing well, but, like, also the companies that are going public are, like, really strong companies with, like, really strong data. You know, companies that have, you know, negative updates, which we'll talk about a couple of those. Yeah. Yeah. You know, those are slowing down pretty dramatically. So it's, you know, the market is the market is strong, but, it is also discerning, you know, which is which is important. So I think, like, healthy. You know, healthy but discerning is, like, a really good way to describe this. Well, I I kinda look at it Yeah. When the markets are on fire, right, everybody can look good as a biotech investor, but it it's the specialty investors, right, of which are a perceptive others. You know? This is where I think, specialty investors thrive. Right? That discernment and understanding, right, where value goes and when the markets are behaving, whether it's on the upside or the downside, I think that favors the the long standing, right, decades long investors who've been doing this for a long time. And I think that's a good thing for our industry. Yep. Absolutely. Absolutely. I think we're seeing, you know, at a general level, right, we're seeing rational responses to data, and that's that's really important. And you've talked a little bit about, which we've noticed, this past year, the kind of a bifurcation of tech and biotech. I mean, we've seen, you know, anthropic, going out in an IPO worth trillions or, over trillion SpaceX, etcetera. And so these tech investors are very different, and the general investors that invest in tech. And so we've seen this, separation, and I know you you had some thoughts on that. Would love to hear your perspective on that. Yeah. Absolutely. So there was a great article this week, from The Wall Street Journal that I loved, that was called health care investing is now an AI short in Disguise, you know, about how, you know, healthcare companies are are really, you …

Get the full transcript (10,558 words) + summary by email — free

One-time email with the complete transcript and AI summary of this episode. No account needed.

One email, no spam. We’ll also show you what SignalCast does.

Browse all Biotech Hangout transcripts →